TW203049B
(en)
*
|
1990-04-13 |
1993-04-01 |
Yamanouchi Pharma Co Ltd |
|
DE4123341A1
(en)
*
|
1991-07-15 |
1993-01-21 |
Thomae Gmbh Dr K |
PHENYL ALKYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
|
DK40192D0
(en)
*
|
1992-03-26 |
1992-03-26 |
Neurosearch As |
IMIDAZOLE COMPOUNDS, THEIR PREPARATION AND USE
|
PH31122A
(en)
*
|
1993-03-31 |
1998-02-23 |
Eisai Co Ltd |
Nitrogen-containing fused-heterocycle compounds.
|
CA2131680C
(en)
*
|
1993-09-17 |
2006-11-07 |
Gerhard Stucky |
Process for preparing imidazopyridine derivatives
|
CA2131134A1
(en)
*
|
1993-09-17 |
1995-03-18 |
Gerhard Stucky |
Process for preparing imidazopyridine derivatives
|
CZ382496A3
(en)
*
|
1994-06-29 |
1997-12-17 |
Smithkline Beecham Corp |
Compounds representing antagonists of vitronectin receptors, process of their preparation, intermediates of such process, pharmaceutical composition containing the compounds and their use
|
US6228871B1
(en)
|
1995-07-10 |
2001-05-08 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
DE19541146A1
(en)
*
|
1995-10-25 |
1997-04-30 |
Schering Ag |
Imidazole derivatives and their use as nitric oxide synthase inhibitors
|
JP2000516611A
(en)
|
1996-08-14 |
2000-12-12 |
ワーナー―ランバート・コンパニー |
2-Phenylbenzimidazole derivatives as MCP-1 antagonists
|
US6051570A
(en)
*
|
1997-05-30 |
2000-04-18 |
Dr. Reddy's Research Foundation |
Benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
|
WO1999001454A1
(en)
*
|
1997-07-03 |
1999-01-14 |
Du Pont Pharmaceuticals Company |
Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
|
IL134748A0
(en)
|
1997-09-02 |
2001-04-30 |
Du Pont Pharm Co |
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
|
US6465484B1
(en)
|
1997-09-26 |
2002-10-15 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
US6162804A
(en)
*
|
1997-09-26 |
2000-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6124463A
(en)
*
|
1998-07-02 |
2000-09-26 |
Dupont Pharmaceuticals |
Benzimidazoles as corticotropin release factor antagonists
|
US6365589B1
(en)
|
1998-07-02 |
2002-04-02 |
Bristol-Myers Squibb Pharma Company |
Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
|
CA2341409A1
(en)
*
|
1998-08-31 |
2000-03-09 |
Merck And Co., Inc. |
Novel angiogenesis inhibitors
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6380235B1
(en)
*
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6365617B1
(en)
|
1999-06-29 |
2002-04-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Indole and indazole urea-peptoids as thrombin receptor antagonists
|
US6858577B1
(en)
|
1999-06-29 |
2005-02-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Indole peptidomimetics as thrombin receptor antagonists
|
AU5895500A
(en)
|
1999-06-29 |
2001-01-31 |
Cor Therapeutics, Inc. |
Novel indazole peptidomimetics as thrombin receptor antagonists
|
US6630451B1
(en)
|
1999-06-29 |
2003-10-07 |
Orthomcneil Pharmaceutical, Inc. |
Benzimidazolone peptidometics as thrombin receptor antagonist
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
MXPA03005298A
(en)
*
|
2000-12-15 |
2003-10-06 |
Vertex Pharma |
Gyrase inhibitors and uses thereof.
|
PL364230A1
(en)
|
2001-03-12 |
2004-12-13 |
Avanir Pharmaceuticals |
Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
WO2003045929A1
(en)
|
2001-11-26 |
2003-06-05 |
Takeda Chemical Industries, Ltd. |
Bicyclic derivative, process for producing the same, and use
|
WO2004024655A2
(en)
|
2002-09-12 |
2004-03-25 |
Avanir Pharmaceuticals |
Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
|
TWI276631B
(en)
|
2002-09-12 |
2007-03-21 |
Avanir Pharmaceuticals |
Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
|
TW200501960A
(en)
*
|
2002-10-02 |
2005-01-16 |
Bristol Myers Squibb Co |
Synergistic kits and compositions for treating cancer
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
WO2006001266A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
Method for producing 2-arylpurine derivative
|
EP1798216A4
(en)
|
2004-09-28 |
2008-12-03 |
Sankyo Co |
Intermediate of 6-substituted-1-methyl-1-h-benzimidazole derivative and method for producing same
|
AU2006212038A1
(en)
*
|
2005-02-08 |
2006-08-17 |
Prosidion Limited |
Dihydroimidazothiazole derivatives
|
NZ562468A
(en)
*
|
2005-04-05 |
2009-10-30 |
Pharmacopeia Inc |
Purine and imidazopyridine derivatives for immunosuppression
|
AU2006279537A1
(en)
*
|
2005-08-15 |
2007-02-22 |
Irm Llc |
Compounds and compositions as TPO mimetics
|
US20090253687A1
(en)
*
|
2005-12-28 |
2009-10-08 |
Shoji Fukumoto |
Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
|
EP1987028A2
(en)
|
2006-02-10 |
2008-11-05 |
Transtech Pharma, Inc. |
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
|
RU2478635C2
(en)
|
2006-10-19 |
2013-04-10 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Heteroaryl compounds, compositions containing them and methods of treating with use of such compounds
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
EP2493472B1
(en)
|
2009-10-26 |
2016-12-07 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
CN107157990B
(en)
|
2011-10-19 |
2020-01-07 |
西格诺药品有限公司 |
Treatment of cancer with TOR kinase inhibitors
|
UA114496C2
(en)
|
2011-12-02 |
2017-06-26 |
Сігнал Фармасьютікалз, Елелсі |
PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE
|
EA028462B1
(en)
|
2012-02-24 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Methods for treating advanced non-small cell lung cancer using tor kinase inhibitor combination therapy
|
TR201807207T4
(en)
*
|
2012-06-11 |
2018-06-21 |
Ucb Biopharma Sprl |
Tnf-alpha modulating benzimidazole compounds.
|
CN103113235A
(en)
*
|
2012-10-15 |
2013-05-22 |
常州大学 |
Method for synthesizing nitryl chloroaniline compound by using micro-channel reactor
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
CN105073744B
(en)
|
2012-12-21 |
2019-11-08 |
齐尼思表观遗传学有限公司 |
Novel heterocyclic compounds as bromine structural domain inhibitor
|
BR112015016997A2
(en)
|
2013-01-16 |
2017-07-11 |
Signal Pharm Llc |
compound, pharmaceutical composition and method for the treatment or prevention of breast cancer
|
US9186361B2
(en)
|
2013-03-15 |
2015-11-17 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
US9233961B2
(en)
|
2013-03-15 |
2016-01-12 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
US9296754B2
(en)
|
2013-03-15 |
2016-03-29 |
Novartis Ag |
Compounds and compositions for the treatment of parasitic diseases
|
CA2908353C
(en)
|
2013-04-17 |
2021-11-02 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
WO2014172426A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
US9358232B2
(en)
|
2013-04-17 |
2016-06-07 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using TOR kinase inhibitor combination therapy
|
BR112015026297B1
(en)
|
2013-04-17 |
2022-08-23 |
Signal Pharmaceuticals, Llc |
USE OF A TOR KINASE INHIBITOR AND 5-SUBSTITUTED QUINAZOLINONE, PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM, AND KIT
|
JP6382948B2
(en)
|
2013-04-17 |
2018-08-29 |
シグナル ファーマシューティカルズ,エルエルシー |
Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for the treatment of cancer
|
US9937169B2
(en)
|
2013-04-17 |
2018-04-10 |
Signal Pharmaceuticals, Llc |
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
|
TW201527300A
(en)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
|
CN113831345A
(en)
|
2013-05-29 |
2021-12-24 |
西格诺药品有限公司 |
Pharmaceutical compositions of dihydropyrazinopyrazine compounds, solid forms thereof and their use
|
JP6461121B2
(en)
*
|
2013-06-21 |
2019-01-30 |
ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. |
Novel bicyclic bromodomain inhibitors
|
ES2661437T3
(en)
|
2013-06-21 |
2018-04-02 |
Zenith Epigenetics Corp. |
New substituted bicyclic compounds as bromodomain inhibitors
|
WO2015015318A2
(en)
|
2013-07-31 |
2015-02-05 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
SI3083627T1
(en)
|
2013-12-19 |
2019-01-31 |
Novartis Ag |
(1,2,4)triazolo(1,5-a)pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
|
EP3105210B1
(en)
|
2014-02-11 |
2019-01-30 |
Bayer Pharma Aktiengesellschaft |
Benzimidazol-2-amines as midh1 inhibitors
|
EA031655B1
(en)
|
2014-02-11 |
2019-02-28 |
Байер Фарма Акциенгезельшафт |
BENZIMIDAZOL-2-AMINES AS mIDH1 INHIBITORS
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
WO2015160882A1
(en)
|
2014-04-16 |
2015-10-22 |
Signal Pharmaceuticals, Llc |
SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
EP3131551A4
(en)
|
2014-04-16 |
2017-09-20 |
Signal Pharmaceuticals, LLC |
SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
JP2017514806A
(en)
|
2014-04-16 |
2017-06-08 |
シグナル ファーマシューティカルズ,エルエルシー |
Methods of treating cancer using TOR kinase inhibitor combination therapy
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
AU2015289929A1
(en)
|
2014-07-14 |
2017-03-02 |
Signal Pharmaceuticals, Llc |
Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
|
EP3209660B1
(en)
|
2014-10-23 |
2020-06-17 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
|
CN107108522B
(en)
|
2014-10-23 |
2020-12-01 |
德国癌症研究中心 |
Benzimidazol-2-amines as mIDH1 inhibitors
|
CA2966303A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
JP2017537946A
(en)
|
2014-12-11 |
2017-12-21 |
ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
WO2016097863A1
(en)
|
2014-12-17 |
2016-06-23 |
Zenith Epigenetics Corp. |
Inhibitors of bromodomains
|
EP3303302B1
(en)
|
2015-06-08 |
2019-03-20 |
Bayer Pharma Aktiengesellschaft |
N-menthylbenzimidazoles as midh1 inhibitors
|
JP6824954B2
(en)
|
2015-07-16 |
2021-02-03 |
ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ |
5-Hydroxyalkylbenzimidazole as an mIDH1 inhibitor
|
SG11201804098TA
(en)
|
2015-11-20 |
2018-06-28 |
Forma Therapeutics Inc |
Purinones as ubiquitin-specific protease 1 inhibitors
|
JP7282045B2
(en)
|
2017-06-22 |
2023-05-26 |
セルジーン コーポレイション |
Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
|
CN111315735B
(en)
*
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
Dihydrobenzimidazolone
|
WO2019079369A1
(en)
|
2017-10-19 |
2019-04-25 |
Effector Therapeutics, Inc. |
Benzimidazole-indole inhibitors of mnk1 and mnk2
|
EP3935050A4
(en)
|
2019-03-06 |
2023-01-04 |
C4 Therapeutics, Inc. |
Heterocyclic compounds for medical treatment
|